Insulet (NSDQ:PODD) reported yesterday that the insulin delivery device-maker topped sales expectations on Wall Street for its fourth quarter and full-year financial results, but missed earnings estimates.
The Billerica, Mass.-based company reeled in losses, posting -$6.9 million on sales of $130.5 million for the 3 months ended Dec. 31, for sales growth of 26% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Insulet beats the Street with Q4, FY17 sales appeared first on MassDevice.
from MassDevice http://ift.tt/2EVqgbw
Cap comentari:
Publica un comentari a l'entrada